全文获取类型
收费全文 | 3131篇 |
免费 | 336篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 97篇 |
妇产科学 | 51篇 |
基础医学 | 474篇 |
口腔科学 | 129篇 |
临床医学 | 399篇 |
内科学 | 692篇 |
皮肤病学 | 86篇 |
神经病学 | 287篇 |
特种医学 | 95篇 |
外科学 | 387篇 |
综合类 | 23篇 |
一般理论 | 3篇 |
预防医学 | 261篇 |
眼科学 | 42篇 |
药学 | 214篇 |
中国医学 | 6篇 |
肿瘤学 | 185篇 |
出版年
2023年 | 65篇 |
2022年 | 43篇 |
2021年 | 96篇 |
2020年 | 71篇 |
2019年 | 76篇 |
2018年 | 126篇 |
2017年 | 120篇 |
2016年 | 123篇 |
2015年 | 131篇 |
2014年 | 144篇 |
2013年 | 255篇 |
2012年 | 219篇 |
2011年 | 227篇 |
2010年 | 137篇 |
2009年 | 87篇 |
2008年 | 130篇 |
2007年 | 155篇 |
2006年 | 146篇 |
2005年 | 123篇 |
2004年 | 147篇 |
2003年 | 107篇 |
2002年 | 100篇 |
2001年 | 32篇 |
2000年 | 12篇 |
1999年 | 16篇 |
1998年 | 18篇 |
1997年 | 13篇 |
1996年 | 19篇 |
1995年 | 25篇 |
1994年 | 11篇 |
1992年 | 21篇 |
1991年 | 17篇 |
1989年 | 13篇 |
1988年 | 12篇 |
1987年 | 12篇 |
1986年 | 20篇 |
1985年 | 14篇 |
1984年 | 23篇 |
1982年 | 16篇 |
1981年 | 11篇 |
1980年 | 12篇 |
1979年 | 15篇 |
1977年 | 11篇 |
1976年 | 11篇 |
1974年 | 10篇 |
1955年 | 38篇 |
1954年 | 88篇 |
1949年 | 20篇 |
1948年 | 17篇 |
1943年 | 11篇 |
排序方式: 共有3470条查询结果,搜索用时 15 毫秒
41.
T. C. EL‐GALALY S. R. KRISTENSEN K. OVERVAD R. STEFFENSEN A. TJØNNELAND M. T. SEVERINSEN 《Journal of thrombosis and haemostasis》2012,10(10):2191-2193
See also Lowe GDO. Epidemiology of venous thromboembolism: the need for large (including prospective) studies and meta‐analyses. This issue, pp 2186–8 and Rosendaal FR. Etiology of venous thrombosis: the need for small original studies. This issue, pp 2189–90. 相似文献
42.
43.
Makio Kusaoi Ken Yamaji Go Murayama Misa Yasui Risa Yamada Ruka Hishinuma Takuya Nemoto Katsura Hohtatsu Michiaki Kageyama Toshio Kawamoto Kaoru Sugimoto Fumio Sekiya Takayuki Kon Michihiro Ogasawara Kazuo Kempe Hiroshi Tsuda Yoshinari Takasaki 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2012,16(5):456-466
Leukocytapheresis (LCAP) is a safe, unique therapy pertaining to intractable rheumatoid arthritis (RA) even in cases of drug allergy or infectious states. To investigate how to represent LCAP efficacy, we have conducted gene expression analyses from the peripheral blood of RA patients treated with non‐woven polyethylene terephthalate filters. Peripheral blood samples were collected immediately before and after treatment from eight RA patients who received LCAP. Among these patients, all of them achieved 20% improvement in the core set of the American College of Rheumatology (ACR20), and thus, they were confirmed as LCAP responders. Gene expression analysis was done with a high‐resolution DNA microarray. The results of each of the two groups' gene expression values (immediately before and after LCAP) were calculated using Welch's t‐test. Calculations were performed with a statistical software R.basic package: if the P‐value was less than 0.05, this was seen as a significant change. In a comparison of 25 370 gene expressions, the number of genes showing a P‐value < 0.05 in the upregulating group was 2110, and in the downregulating group it was 1864. The results of pathway analysis using the MetaCore program indicate that gene groups work for cytoskeletal remodeling are upregulated, and genes related to immune responses, such as antigens presenting via major histocompatibility complex class I and II, are downregulated just after LCAP. These findings may relate to LCAP efficacy for RA patients, but this needs further investigation. 相似文献
44.
45.
46.
Hironori Tsujimoto Hiroyuki Horiguchi Risa Takahata Satoshi Ono Yoshihisa Yaguchi Shinsuke Nomura Nozomi Ito Manabu Harada Hiromi Nagata Yusuke Ishibashi Keita Kouzu Satoshi Tsuchiya Yujiro Itazaki Seiichiro Fujishima Yoji Kishi Hideki Ueno 《Journal of gastroenterology and hepatology》2020,35(5):788-794
47.
Risa Konishi Ryota Tanaka Sae Inoue Yuki Ichimura Toshifumi Nomura Naoko Okiyama 《The Journal of dermatology》2022,49(1):118-123
Dermatomyositis, an idiopathic inflammatory myopathy, is characterized by cutaneous itchy manifestations, which are frequently refractory and recurrent even after intensive immunosuppressive treatments. To evaluate the effectiveness and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in treating skin-dominant dermatomyositis in which myositis and interstitial lung disease are absent or in remission, we performed this prospective, single-arm, interventional study. A total of five Japanese patients (one male and four females, median [range] age, 64 [37–71] years) with refractory dermatomyositis-associated cutaneous manifestations were recruited and treated with a 12-week course of oral apremilast. Among five enrolled patients, three experienced diarrhea with full-dose apremilast (30 mg twice daily), two of whom withdrew from the study and recovered quickly afterwards. A total of three evaluable female patients (median [range] age, 65 [64–71] years) received apremilast treatment for 12 weeks. A 39.4% reduction from baseline Cutaneous Dermatomyositis Disease Area and Severity Index total activity score, but not the damage score, at week 12 was observed in all three patients. Visual analog scale of itching, and quality of life by Dermatology Life Quality Index were slightly improved in one and two apremilast-treated patients, respectively. As apremilast was effective, with expected and recoverable digestive adverse events (diarrhea), in patients with refractory and recurrent dermatomyositis-associated cutaneous manifestations in this first phase Ib study, it can be suggested as a possible treatment when aggressive immunosuppressive therapies with high-dose systemic corticosteroid and/or immunosuppressive agents for other manifestations, myositis, and interstitial lung disease, are not required. 相似文献
48.
49.
Koji Kimura Risa Takayanagi Haruko Yokoyama Yasuhiko Yamada 《Rheumatology international》2012,32(1):145-150
In Japan, the recommended dosage regimens of infliximab (IFX) for treatment of rheumatoid arthritis (RA) and Crohn’s disease
(CD) are different. However, the differences have not been analyzed theoretically. In a previous study, we constructed a pharmacokinetic–pharmacodynamic
model to investigate the effects of IFX for CD and found it useful to establish a rational dosage regimen of IFX for individual
patients with CD. In the present study, we investigated whether the theory-based model could be used for cases of RA and also
used it to evaluate the validity of the dosage regimen. The results obtained with our model were in good agreement with observed
tender joint count (TJC) ratio data, which was considered to show the validity of our analysis. Thus, we concluded that the
model could be used for patients with RA. Furthermore, a second administration of IFX given 2 weeks after the first infusion
was important to achieve remission in the early stage of RA. We also compared the estimated pharmacodynamic parameters of
RA with those of CD. The elimination rate constant of inflammation in RA was greater than that in CD, suggesting that the
recovery from inflammation in RA is faster than that in CD, and indicating a reason for the difference in dosage between RA
and CD. In conclusion, use of our model in light of the individual quantitative factor of tumor necrosis factor (TNF)-α allows
establishment of IFX dosage regimens for individual patients. 相似文献
50.
Immunohistochemical expression profiles of solute carrier transporters in alpha‐fetoprotein‐producing gastric cancer
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)